- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Clarence Moore Discusses Patient Accessibility to Beta Thalassemia Treatments
Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses whether treatment methods for beta thalassemia are accessible to patients.
Transcript:
How accessible are treatments for beta thalassemia? What is the process for patients and where can they go for support?
It all depends on what region of the country individuals are from. Historically, the treatments were specifically just blood transfusion. So, you could potentially get blood transfusions and various locations. But the more transfusions an individual has had, the more types of antigens they will be exposed to.
So, being able to receive blood that is matched specifically to them I think is very important. I'm looking at some of the treatments. I'm definitely looking at various formularies, [like] chelation therapy, to determine which products may be approved by one's insurance or which one is going to be recommended based on the recommendation of the physician or the medical team. I think that is also something of importance.
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
